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ABSTRACT
Ubiquitin specific proteases (USPs) reverse
ubiquitination and regulate virtually all cellular
processes. Defined non-catalytic domains in USP4
and USP15 are known to interact with E3 ligases
and substrate recruitment factors. No such
interactions have been reported for these domains
in the paralog USP11, a key regulator of DNA
double-strand break repair by homologous
recombination (HR). We hypothesized that USP11
domains adjacent to its protease domain harbour
unique peptide-binding sites. Here, using a next-
generation phage display (NGPD) strategy,
combining phage display library screening with
next generation sequencing, we discovered unique
USP11 interacting peptide motifs. Isothermal
titration calorimetry disclosed that the highest
affinity peptides (KD of ~10 μM) exhibit exclusive 
selectivity for USP11 over USP4 and USP15 in
vitro. Furthermore, a crystal structure of a USP11-
peptide complex revealed a previously unknown
binding site in USP11’s non-catalytic ubiquitin-like
(UBL) region. This site interacted with a helical
motif and is absent in USP4 and USP15. Reporter
assays using USP11-WT versus a binding pocket-
deficient double mutant disclosed that this binding
site modulates USP11’s function in HR-mediated
DNA repair. The highest affinity USP11 peptide
binder fused to a cellular delivery sequence induced
significant nuclear localization and cell cycle arrest
in S phase, affecting the viability of different
mammalian cell lines. The USP11 peptide ligands
and the paralog-specific functional site in USP11
identified here provide a framework for the
development of new biochemical tools and
therapeutic agents. We propose that an NGPD-
based strategy for identifying interacting peptides
may be applied also to other cellular targets.
There are ~54 ubiquitin specific proteases
(USPs) encoded in the human genome, most of
which harbour a canonical cysteine protease
catalytic triad. USPs specifically reverse
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ubiquitination of a range of substrates to regulate
virtually all cellular processes including protein
degradation, signalling pathways, DNA damage
repair, transcription and receptor endocytosis (1).
USPs harbour a catalytic domain that is flanked or
interspersed by additional domains for versatile
functionality and specificity (2,3). For most USPs,
interactions involving these domains are poorly
understood, and only few selective agents to probe
a particular USP’s function are available (4-10).
Human ubiquitin specific protease 11 (USP11) is
best known for its role in DNA damage repair by
homologous recombination (HR) (11,12).
Knockdown of USP11 results in spontaneous
activation of the DNA damage response and
sensitivity to genotoxic stress agents (13) and
ionizing radiation (14). DNA damage repair by HR
mostly occurs in S and G2 phases of the cell cycle
and is suppressed in G1. As part of the mechanism
controlling this process, USP11 regulates the
ubiquitination status of the BRCA2-PALB2
complex and USP11 is upregulated in S phase (12).
USP11 silencing also inhibits TGFβ pathway 
signalling (15) and USP11 is involved in NF-B
signalling pathways. The stability of several other
important proteins relevant to health and disease is
regulated by USP11, including p21 (16), RAE1
(17) and cIAP2 (18). Consistent with an important
regulatory role, USP11 is dysregulated in a number
of cancers including pancreatic cancer (19), glioma,
ovarian and breast cancers, as well as hematological
malignancies (12).
USP11 harbours a core protease domain as
well as non-catalytic regions containing an N-
terminal domain present in USPs (DUSP) and
internal ubiquitin-like (UBL) domains (20) (Fig.
1A). USP11 shares this domain architecture with
paralogs USP15 and USP4, which are known as the
DUSP-UBL (DU) family of USPs (20-23).
We previously determined the crystal structure of
the USP11 N-terminal DU domains and showed
that USP11’s non-catalytic domains do not directly
auto-activate or inhibit the activity of USP11 (20).
In contrast, the USP4 N-terminal DU domains are
required for efficient turnover of the enzyme by
promoting ubiquitin release (24). The USP4 and
USP15 DU domains interact with E3 ligases (25)
and the substrate recruitment factor SART3
(26,27), but no interactions have yet been reported
for these domains in USP11. We hypothesized that
USP domains adjacent to the protease domain
would be good targets for the identification of
unique binding sequences as they significantly
differ between USPs. Here, a next generation phage
display (NGPD) approach was applied to screen for
peptide ligands against the USP11 N-terminal
domains. NGPD combines the diversity of phage
display libraries with the screening capability of
next generation sequencing platforms. This allows
the replacement of immunoassay screening of
several hundred randomly picked phage clones
after conventional phage panning with the more
comprehensive analysis of the sequence of
potentially millions of ligand genes to determine
enrichment of particular sequences which can then
be selected for screening in biochemical assays.
This method has been applied previously to the
identification of peptides with specific binding
traits (28-30). We discovered USP11 specific
peptides harbouring consensus motifs that do not
interact with either paralog USP4 or USP15 and
identified a novel binding site in the USP11 N-
terminal ubiquitin-like domain. Together, the data
show that the NGPD strategy can be used to
uncover highly selective ligands and novel binding
sites for USPs as a basis for the development of new
probes or anti-proliferative agents.
Results
A next generation phage display strategy for the
isolation of USP11 peptide ligands
A NGPD approach was applied to the
identification of USP11 ligands as schematically
depicted in Fig. 1B. A randomized linear peptide
library fused to the gpVIII protein was used in order
to isolate peptides that interact with the USP11 N-
terminal DU domains (DUSP and UBL domains in
tandem; USP11_DU; Fig. 1A). After three
biopanning rounds, phage ssDNA was extracted,
purified and peptide sequences amplified and deep
sequenced. In order to rank the identified
sequences, a two proportion Z test based method
(31,32) was applied to round 3 output phage and
analysis of the 50 sequences with the highest Z
scores after three rounds of panning (Fig. S1)
revealed the presence of two sequence motifs:
[YNHC]-[+-]-L-[+-]-ɸ-R (motif 1, based on 18 
peptides) and a L-x-L-ɸ-x-x-S-[RP] (motif 2, based 
on 29 peptides) whereby x stands for any residue,
[+-] for charged residues and ɸ for non-polar 
residues. A graphical representation of the residue
frequency within the motifs as computed by the
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Multiple EM for Motif Elicitation (MEME)
algorithm (33) is shown in Fig. 1C. The
thermodynamic binding parameters of synthetic
peptides representative of both motifs including the
N-terminal phage protein sequence (AEGEF),
AEGEFYKLKIRTPQ (referred to as FYLIR
peptide) and AEGEFLELLKASRW (referred to as
LxLL peptide), were determined by isothermal
titration calorimetry (ITC). Peptides harbouring
either motif bound USP11_DU with dissociation
constants of about 10 μM (8.86 ± 1.13 μM for 
AEGEFYKLKIRTPQ and 6.92 ± 2.25 μM for 
AEGEFLELLKASRW; Fig. 1D). We subsequently
focused on the FYLIR peptide and showed that full-
length USP11 and its N-terminal domains alone
display comparable dissociation constants
indicating that the presence of the protease domain
has no influence on the interaction (Fig. S2).
A helical motif in the peptide ligand binds to a
novel USP11 UBL domain binding site
At present no binding sites or interaction
partners have been identified for the USP11 N-
terminal domains. We therefore focused on
exploring the molecular basis of the interactions
between USP11 and the peptide ligand. Co-
crystallization trials of USP11_DU in the presence
of FYLIR peptide yielded monoclinic crystals of
space group P21 that diffracted to 1.3 Å resolution
after optimization. The structure was determined by
molecular replacement and refined to an Rwork/Rfree
of 15.7/17.8%. Data collection and refinement
statistics are summarized in Table 1. The DUSP and
UBL domains in the peptide complex structure are
arranged in tandem (Fig. 2A), analogous to the
structures of the rat USP11 orthologue (20) and
homologues USP4 (SGC) and USP15 (21,22), but
unlike the previous structure of human USP11_DU
(20). Unexpectedly, the structure revealed that the
peptide occupied an elongated cleft in the USP11
UBL domain (Fig. 2), with clear electron density
for peptide residues Gly3-Arg14 observed in both
copies of the asymmetric unit (Fig. S3A). The
peptide’s main interacting core comprises nine
residues (residues 5-13; FYKLKIRTP) (Fig. 2C,
D), with a buried interaction interface area of ~750
Å2. Interestingly, peptide residues Glu2-Lys7 adopt
an α-helical conformation when in complex with 
USP11, which is stabilized by T-shaped π-π 
stacking interactions of residues Phe5 and Tyr6.
Phe5, which can be described as the first tooth of
the bidentate-like interaction, is nearly completely
buried by occupying a hydrophobic pocket
(referred to as major pocket). Tyr6 is partially
solvent exposed and engages in additional contacts
with the USP11 UBL domain.
The pocket is formed predominantly by side
chains of USP11 residues His161, Trp200, Leu208,
Ile230, Glu232, Pro241, Ser242 and Leu245.
Hydrogen bonding interactions between main chain
carbonyls and amine groups of peptide residues
Lys9, Arg11 and USP11 Leu208 are also key
features of the interaction (Fig. 2C, D). The
peptide’s Ile10 occupies a second hydrophobic
pocket (USP11 Leu245, Trp200). Ile10 “anchors”
the peptide together with the guanidinium group of
FYLIR peptide Arg11 that forms a salt bridge with
USP11 Asp209 in what could be described as the
‘second tooth’ of the bidentate-like interaction. The
peptide’s Arg11 is also in close proximity to
another acidic residue, USP11 Glu205 (Fig. 2C).
Compared to the unliganded USP11 UBL domain
(PDB code 4MEL (20)), minor conformational
changes in the structure are observed. The side
chain of His161 partially masks the pocket in the
unliganded structure. The loop between strands S3
and S4 in the UBL domain (S3S4 loop, residues
N203-S207) becomes less flexible in the peptide
bound structure due to interactions of USP11
Glu205 with the peptide’s Arg11. Moreover, a
flexible-to-order transition of Leu245 due to
interactions with the peptide’s Phe5 is also
observed between the unliganded and liganded
USP11_DU structures (Fig. S3B).
The ‘FYLIR’ peptide ligand is highly specific for
USP11 in vitro
USP11 shares its domain structure with
USP4 and USP15 (20-24). The USP11 UBL
domain shares 32% sequence identity with the
corresponding UBL domains in USP4 and USP15,
whereas these domains in USP4 and USP15 share
72% sequence identity (Fig. 3). We therefore tested
whether the peptide ligand is specific for USP11.
Interestingly, an interaction between FYLIR
peptide and the DU domains of either USP4 or
USP15 by ITC was not observed, suggesting that
this binding cleft for the peptide is specific to
USP11 (Fig. 4C). A superposition of the three
structures revealed differences in the main USP11
binding pocket (‘major pocket’) compared to
USP15 and USP4 (Fig. 4A, B). In particular,
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USP11 Leu208 is substituted by Phe188 and
Tyr192 in USP15 and USP4, respectively. At the
position of USP11 Ser242, USP15 and USP4
harbour arginine residues Arg222 and Arg226,
respectively (Fig. 3, 4A). The arginine residues are
engaged in π-stacking and ion-π interactions with 
the aromatic side chains of USP15 Phe188 and
USP4 Tyr192 and consequently occlude the pocket.
Therefore, the smaller side chains of Leu208 and
Ser242 may be the key residues that allow USP11
to engage with the peptide ligand.
To further verify the key role of this pocket
for ligand binding in solution, we generated a
USP11_DU Leu208Phe and Ser242Arg double
mutant (USP11_DU L208F, S242R) to render this region
USP15-like. USP11_DU and USP11_DU L208F, S242R
behaved similarly on gel filtration. No aggregation
and an equivalent elution volume was observed for
the mutant disclosing that the mutations are
compatible with folding resulting in a similar
hydrodynamic radius to USP11_DU. Furthermore,
FL-USP11 L208F, S242R was active (Fig. S4). ITC
experiments confirmed that ligand binding to
USP11_DU L208F, S242R was abolished (Fig. 5A). We
also investigated whether this binding pocket is
involved in interactions with motif 2 (LxLL
peptide). ITC experiments with the USP11 pocket-
deficient double mutant USP11_DU L208F, S242R and
this peptide resulted in no detectable binding,
showing that both peptide binding motifs require
the ‘major pocket’ for interaction with USP11 (Fig.
5B). Whether in addition to altering the pocket
region, these mutations affect the conformation of
FL-USP11 is not known.
The UBL binding pocket of USP11 is required for
its function in homologous recombination
The ITC data showed that peptides
harbouring either motif interacted with the major
pocket in the UBL domain. USP11 is most well-
known for its role in DNA damage repair by
homologous recombination (HR) (11,12) and
depletion of USP11 results in HR repair defects
(13,14). In order to explore whether the identified
binding site is required for USP11 function, HR
GFP-reporter assays were carried out in U20S-DR3
reporter cells (34). These cells contain an integrated
non-functional GFP gene, which has been
interrupted by inclusion of an I-Sce1 restriction site.
Also contained within the integrated region is
another incomplete GFP sequence that can be used
as a template for HR repair across the I-Sce1 site. A
double strand break within the reporter can be
induced by expression of the nuclease I-Sce1 and
reconstitution of the GFP gene and subsequent
expression of functional GFP protein can be used as
a marker of successful HR-mediated repair. To this
end, the formation of GFP products was measured
from the integrated substrate in USP11 depleted
cells transfected with I-Sce1 (34), and
complemented with USP11wt or the UBL binding
site mutant USP11L208F, S242R (Fig. 5C). The
percentage of GFP positive cells normalised to the
RFP transfection efficiency was significantly lower
in the case of the USP11 binding site mutant
compared to USP11wt and similar to the RFP
control. This shows that the USP11L208F, S242R
mutant cannot complement USP11wt for HR
indicating the importance of this binding site for
USP11’s function in HR, either directly or due to its
contribution to the conformation of the enzyme.
Transduction of a ‘FYLIR’ peptide agent results
in differential effects on cell viability
It was hypothesized that peptide binding may
affect the catalytic turnover of substrates by steric
hindrance as the peptide binding site is located in
proximity to the catalytic triad in the protease
domain. When the impact of the FYLIR peptide on
the USP11 catalytic activity was assessed using the
model substrates 7-amino-4-methylcoumarin
modified ubiquitin (Ub-AMC) and K63-linked
FRET di-ubiquitin carboxytetramethylrhodamine
(TAMRA), the observed slight reduction in
catalytic activity was not statistically significant
compared to controls (unpublished observation).
We next evaluated the effect of the FYLIR peptide
ligand on cells in culture. The novel GET system,
developed for highly efficient nucleic acid, protein
and peptide delivery (35), was used to deliver the
FYLIR peptide. GET is based on the use of cell-
penetrating peptides modified with heparin-binding
sequences, which enhance cellular uptake by
endocytosis. The synthetic peptide, GET-FYLIR,
designed for these studies harboured an N-terminal
TAMRA fluorescent tag, for easy visualization,
fused to the GET (P21 and 8R (35)) and FYLIR
sequences. GET-FYLIR was efficiently delivered
to all cell lines tested (including human
glioblastoma KNS-42 and U87, cervical carcinoma
HeLa, mammary carcinoma MCF7, pancreatic
carcinoma Panc1, and fibroblast NIH3t3 and BJ6
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cell lines). Confocal imaging of HeLa cells, treated
for 24 hours with a low dose of GET-FYLIR (10
µM) showed localization of the GET-FYLIR
peptide in both the cell cytoplasm and the nucleus;
with the highest accumulation in nucleoli (Fig. 6A).
This showed that the GET-FYLIR peptide is
efficiently delivered to subcellular compartments
where endogenous USP11 protein is localized (36)
and that the GET-FYLIR peptide efficiently
escapes endosomal vesicles (as endosomal escape
can be a limitation for delivered peptides). Having
established efficient delivery, the peptide’s effect
was investigated by assessing cell viability.
Interestingly, a significant cell-type specific
decrease in cell viability upon delivery of the GET-
FYLIR peptide (up to 50 μM) was observed (Fig. 
6B). Panc1 cell lines were particularly sensitive to
GET-FYLIR dose, whereas other cell lines,
especially BJ6 human dermal fibroblasts, were
relatively insensitive. After 24 h incubation with 10
μM of GET-FYLIR, Panc1 cells showed a loss of 
viability (~50%); an almost complete loss of
viability (to ~12%) was observed at a dose of 20
μM. Viability of BJ6, U87 and NIH3t3 cell lines 
was retained at 10 μM dose with a minimal effect 
at a 20 μM dose. In order to confirm that the 
differential effect on cell viability was not due to
peptide uptake efficiency, GET-FYLIR initial
uptake (1 h) and long-term uptake (24 h) with low
dosages in NIH3t3 cells (a relatively insensitive cell
line) were compared to uptake in Panc1 cells (a
sensitive cell line to GET-FYLIR dose) (Fig. S5).
The lowest dose tested (1 μM; Fig. S5A) showed 
little difference in cell uptake in either cell-type for
short (1 h) or long (24 h) exposures. Importantly,
uptake increased with longer exposures. However,
at a higher dose (5 μM; Fig. S5B), cell viability
effects in Panc1 but not NIH3t3 cells were
observed, with increased uptake in Panc1 cells for
both 1 h and 24 h incubations. Interestingly, the
uptake was similar at 1 h and 24 h incubations for
Panc1 cells at this higher dose. This possibly
suggests that cell membrane permeability may have
been affected even after 1 h incubation in Panc1
cells. Uptake by NIH3t3 cells was significantly
lower than Panc1 cells at this dose for both
incubation times. These data suggests that the GET-
FYLIR peptide is similarly taken up in the different
cell lines, but that uptake is significantly altered
once the concentration begins to compromise cell
viability. In order to confirm that GET-FYLIR was
specifically producing this change in cell viability
and uptake, a scrambled control peptide where the
FYLIR sequence was replaced by the sequence
APKFEIRRGTYKLE (GET-Scrambled) was also
used. The scrambled peptide was efficiently
delivered and there was no difference in the uptake
profile between NIH3t3 and Panc1 cells.
Furthermore the GET-Scrambled peptide had no
significant effect on Panc1 cells (up to 10 µM) (Fig.
S6). This suggests therefore that cell-type specific
changes in cell uptake, at dosages in which the cell
viability was compromised, were attributable to the
activity of the FYLIR peptide.
In order to further characterize the effect of
the GET-FYLIR peptide, cell cycle analysis was
conducted on cell lines that were GET-FYLIR
sensitive (Panc1) and relatively resistant (NIH3t3).
Using genome copy number analyses by flow
cytometry, we demonstrated that Panc1 cells
treated with GET-FYLIR (20 µM) showed a
significantly increased fraction of cells in S phase
(36.9% to 52.8%; p<0.0001; n=7), as well as
significant alterations in all other fractions (Fig.
6C). In NIH3t3 cells, GET-FYLIR had smaller
effects on cell cycle distribution (24.8% to 37.5%,
p<0.0001, n=5). Furthermore, in Panc1 cells, the
subG0 fraction (cells containing less than one
diploid genome) increased ~9-fold (0.9% to 8%;
p<0.0001; n = 7), whereas this effect was not
significant in NIH3t3 cells (0.2% to 0.8%:
p=0.9992: n=5), suggesting DNA fragmentation
and cell death is triggered in Panc1 cells by GET-
FYLIR. These results suggest that, when efficiently
delivered to cells, FYLIR has a cell-type specific
effect on cell viability, associated with cell cycle
arrest and S phase progression.
Discussion
The present study describes the discovery for
the first time of unique peptide ligands for a
ubiquitin specific protease by the means of next
generation phage display. The highest affinity
peptide with a ‘FYLIR’ motif interacts with USP11
with a dissociation constant of ~10 μM. This ligand 
is highly specific for USP11 by occupying an
unexpected unique site in the N-terminal UBL
domain that is neither present in the paralogs, USP4
and USP15, or any of the other USPs encoded in
the human genome. UBL domains are often
involved in interactions and occur frequently in
USPs (37). In the most well studied member of the
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USP family USP7, UBL domains recognize
binding motifs in the epigenetic regulators UHRF1
(38) and DNMT1 (39) amongst other binding
partner proteins (40), but this is achieved through
different recognition surfaces. The USP11 crystal
structure showed that both the S3-S4 loop that is
often involved in engaging binding partners in UBL
domains (41) as well as a conserved unique C-
terminal sequence extension to the UBL core
(sequence WPSAQL) are part of the peptide
binding site.
A single to double-digit micromolar starting
affinity, as reported here, is often observed for
peptide identification from phage display. For
example, peptides isolated to Japanese encephalitis
virus, insulin-degrading enzyme or IL17A had
affinities in the 2.5-12 μM range (42-44). 
Subsequent affinity maturation has been
successfully employed to achieve affinities in the
nanomolar range (42). Additional peptide phage
libraries can also be constructed by randomizing the
residues which are adjacent to the ones critical for
the interaction (soft randomization) based on
structural information and thus improve the affinity
of the parental FYLIR peptide. This will be the
focus of future investigations.
For the majority of USPs the roles of non-
catalytic regions, such as the N-terminal
USP11_DU domains, are poorly understood.
However, USP7 accessory domains have been
shown to have unique specificities, where [PA]-x-
x-S motifs in p53, Hdm2 and Epstein-Barr nuclear
antigen 1 are recognized by a central binding cleft
in the N-terminal TRAF-like domain (45) and the
USP8 rhodanese domain harbours a ligase
recognition site (46). Knowledge of binding sites
and the availability of agents targeting the non-
catalytic domains can be beneficial for drug
discovery programmes due to the potential for
increased selectivity compared to active site
inhibitors. This is the first report of specific binding
sequence motifs for USP11. A high resolution
crystal structure revealed a binding mode with a
helical segment that bears hallmarks of typical
peptide-protein interactions such as an amphiphilic
nature and the presence of a leucine, tyrosine,
isoleucine and phenylalanine at the interface (47).
Interestingly, both peptide motifs identified in this
unbiased NGPD approach use the major pocket for
interactions. In addition, a role of this binding site
in homologous recombination assays was
confirmed by comparing USP11wt and the binding
pocket- deficient mutant USP11L208F, S242R. This
may be due to a direct contribution of the particular
mutated residues to interactions, but could in
principle also be due to a change in enzyme
conformation.
Furthermore, a fluorescently labelled peptide
agent was designed and showed efficient
transduction of several cell lines. Interestingly, the
FYLIR peptide based agent blocked cell
proliferation and affected viability by arresting the
cell cycle predominantly in S phase. USP11’s role
in DNA damage repair by homologous
recombination, which is important in S phase and is
highly suppressed in G1 (12), is consistent with the
peptide’s effects being, at least in part, attributed to
interference with USP11 function. Indeed, mutation
of the FYLIR peptide’s USP11 binding site affected
homologous recombination in U2OS cells. A
significant fraction of USP11 localizes to chromatin
in cells before and upon induction of DNA damage
(13). The GET-FYLIR peptide localizes with the
USP11 subcellular distribution and is enriched in
nucleoli.
Several reports link USP11 to cell cycle
progression and proliferation although the detailed
mechanisms are only partially understood. For
example, (i) cell growth assays in MCF-7 and
MDA-MB-231 cells show an increase in cell
numbers upon USP11 overexpression, while
USP11 knockdown leads to growth inhibition (48);
(ii) USP11 itself is under cell cycle control and
turns over rapidly in G1 cells, especially upon DNA
damage induction, whereas expression of USP11 in
S phase is high and insensitive to DNA damage
(12). Knockdown of USP11 results in the activation
of DNA damage response pathways, leading to
hypersensitivity of cells to genotoxic stress (13);
(iii) in primary human fibroblasts knock-down of
USP11 results in characteristics of senescence,
including proliferative arrest and enlarged nucleoli
(49) and (iv) USP11 interacts with p21 to regulate
cell cycle progression and DNA damage responses
(16). Interestingly, we found that in Panc1 cells that
have previously been shown to have high amounts
of USP11 mRNA and undergo dose dependent cell
death upon treatment with mitoxantrone that
inhibits USP11 (19), cell viability is highly affected
by FYLIR peptide exposure. USP11 has been
recognized as a novel anti-cancer target by
preventing repair of double strand breaks in cancer
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cells via synthetic lethality (11). Nevertheless,
further studies will be required to decipher the
detailed mechanism of action of the GET-FYLIR
peptide agent.
Taken together, we identified USP11
interaction motifs, a novel binding site in the
USP11 UBL domain and demonstrate the ability of
a peptide agent containing a USP11 interaction
motif to differentially affect cell lines. Therefore, as
well as providing insight into USP11 recognition,
the findings may also pave the way for the
development of novel peptidomimetic agents. To
our knowledge, outside of epitope mapping, this is
the first example of using NGPD to define protein-
binding motifs. The strategy will be applicable to
other members of the USP family for the
identification of unique ligands and binding sites
and the development of molecular probes and/or
therapeutic agents.
Experimental procedures
Constructs
DNA constructs for this study were
generated by standard molecular biological
techniques. Constructs of human USP11 spanning
the DUSP-UBL domains (USP11_DU), residues 1-
244 or 24-244, USP11 (1-920) as well as
USP15_DU and USP4_DU in pET26b and FL-
USP11 in pColdI have previously been described
(20,21). The double mutants USP11_DU L208F, S242R
and FL-USP11 L208F, S242R were generated by site
directed mutagenesis using the QuickChange
method. For HR assays, FL-USP11 was cloned into
the cDNA3.1(+)mRFP vector using KpnI and XhoI
restriction sites and a corresponding construct
harbouring L208F and S242R mutations created by
the QuickChange method.
Protein production
All proteins were expressed and purified
according to protocols described previously (20).
Protein expression was induced by adding 0.5 mM
IPTG to BL21-CodonPlus cell cultures grown at
37 °C in 2xYT medium to mid-log phase. Cells
harboring the USP11_DU (residues 1-244 or 24-
244), the double mutant USP11_DU L208F, S242R,
USP15_DU, and USP4_DU plasmids were
harvested after 4 h. For FL-USP11 constructs, cells
were grown for 72 h at 10 °C. For all DU constructs
cells were lysed by sonication in 20 or 50 mM Tris-
Cl pH 7.5, 150 mM NaCl, 20 mM imidazole. Cells
containing FL-USP11 were lysed in 50 mM Tris-
Cl, 300 mM NaCl, 5% (v/v) glycerol, 20 mM
imidazole. Samples were purified using HiTrap
chelating columns (GE Healthcare) precharged
with nickel sulfate. Size exclusion chromatography
was performed using a Superdex 75 16/60 column
(GE Healthcare) pre-equilibrated with 50 mM Tris-
Cl, pH 7.5, and 150 mM NaCl for the DU constructs
or a Superdex 200 16/60 column (GE Healthcare),
pre-equilibrated with 50 mM Tris-Cl, pH 7.5, 300
mM NaCl, and 1% glycerol for the FL-USP11.
Phage display and biopanning
The peptide phage display library used for
biopanning experiments (kindly provided by
Professor Franco Felici, University of Molise, Italy;
designated PC89VIII) is based on the PC89
phagemid vector (50) with a nonapeptide inserted
at the N-terminus of the phage major coat protein
pVIII and a reported diversity of approximately 107.
The library was transformed into E. coli TG1 supE
thi-1 ∆(lac-proAB) ∆(mcrB-hsdSM)5(rK–mK) 
[F ́traD36 proAB lacIqZ∆M15] which was the 
strain used for all manipulations and phage rescue.
Libraries were grown to mid-log phase
(OD600~0.6), superinfected with M13KO7 helper
phage (Pharmacia LKB) and incubated overnight at
30 °C (250 rpm) to produce phage particles. Phage
was harvested and PEG precipitated only for the
first panning round. For all subsequent selection
rounds (3 in total) supernatant phage was used
directly. Biopanning was carried out once as
previously described (51) and proteins were
immobilized on cobalt beads (Dynabeads) (solution
phase panning). A total of 100 μg of USP11_DU 
was immobilized for each round. In parallel, the
phage isolated at each round against USP11_DU
were also bound against an unrelated His-tagged
control protein under the same conditions. This
control protein was a fragment of flagellin, a
virulence factor from E. coli O157:H7, amino acid
residues 164 to 495, the protein was used as it is
unrelated to the target proteins and carried a C-
terminal His-tag. Bound phage were washed 10 to
20x with PBS (10 mM phosphate buffer pH 7.2-7.4
with 150 mM NaCl) plus 0.1% (v/v) Tween (PBST)
and then PBS. Bound phage were eluted from the
beads with 100 mM triethylamine and neutralized
in 1 M Tris pH 7.4. Half of the eluted phage was
used for infection of TG1 cells, which were plated
and used to make glycerol stocks.
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Deep sequencing
The ssDNA of eluted phage for round 3 of
selection against the USP11_DU target and the
control protein was extracted and purified using the
QIAprep Spin M13 Kit. Subsequently, phage
ssDNA was precipitated with ethanol and stored as
a dry pellet to be used as a PCR template. For the
amplification of the unknown peptide sequences, a
two-step PCR strategy was followed as previously
described (32). The strategy produced an amplicon
of approximately 330 bp and each sample contained
a unique barcoded sequence. Each sample’s DNA
concentration was determined by the Agilent 2100
Bioanalyser using the DNA 1000 kit. Based on the
concentration readings for the peak of interest
samples were pooled in equal amounts, purified by
the Agencourt AMPure XP kit and run on a 2%
(w/v) agarose gel. The band of ~330 bp was excised
from the gel and purified using the NucleoSpin Gel
and PCR Clean-up kit. Finally, the concentration
and size of the pooled DNA was measured on a
Bioanalyser. NGPD was carried out once for each
round of panning.
Ion torrent data file processing and sorting of
sequences
Deep sequencing of all samples was
performed using an Ion Torrent PGM technology
commercial service by the Department of
Biochemistry at the University of Cambridge on a
318 chip. Approximately 500 Mbase of readings
were obtained per chip, which translates to ~105
reads on average per barcode and a mean length of
100 bp. The number of meaningful reads per
panning round for each sample was found to be
approximately 4x104. Subsequently, processing of
all sequences in quality FASTQ file format was
conducted. The first processing step consisted of
the demultiplexing of the FASTQ file in order to
sort the sequences according to their barcodes and
generate individual FASTQ files, each representing
the repertoire of peptides eluted from one of the
panning rounds binding to either the target protein
or the control protein. Each FASTQ file was then
converted to FASTA format, translated in all three
reading frames and concatenated into one file
containing all frames. Using Perl scripts, only
sequences of interest, flanked between conserved
PC89 gpVIII protein sequences (AEGEF and
DPAKAA motifs were used), were kept in a single
file. The peptide sequence repertoires of eluted
polyclonal phage binding to either the protein of
interest or the control protein were then compared.
Ultimately, all sequences were exported to excel
files with frequencies: the number of copies of the
sequence isolated against the target protein and the
number of copies of the same sequence isolated
against the control protein. A two proportion Z test
was then used to compare the sequence populations
and sort them by Z scores which reflects the ratio as
well as the absolute frequencies of each peptide
sequence and allows their ranking by relative
statistical importance (31). For peptide motif
generation from the obtained sequences the MEME
algorithm was used (33).
Isothermal titration calorimetry (ITC)
ITC data were measured on a MicroCal VP-
ITC or a PEAQ ITC instrument to obtain the
binding parameters for peptide ligand-USP11_DU
interactions. The sample cell contained 30 μM 
protein in PBS buffer. Each peptide (at a
concentration of 300 or 600 μM) was titrated into 
the sample cell in 8 μl (VP-ITC) or 2 μl (PEAK 
ITC) injections at a temperature of 25 °C. Spacing
was typically 180 sec and a stirring speed of 300
rpm was used. The data were analysed using
NITPIC (52), SEDPHAT (53) and GUSSI software.
ITC experiments were repeated at least twice
independently apart from the USP15_DU,
USP4_DU and the FL-USP11 titrations with
FYLIR peptide, which were conducted once.
Protein crystallization, data collection and
structure determination
Samples of the USP11 DUSP-UBL domains
(residues 24-244) at concentrations of 4 and 8
mg/ml in 100 mM NaCl, 50 mM Tris-Cl, pH 7.5,
1% glycerol were mixed with the FYLIR peptide
(AEGEFYKLKIRTPR) at a ratio 1:4 and
crystallization trays were set up by the sitting drop
vapour diffusion method at 10 °C. Crystals grew
within 3 days and the initial conditions were further
optimized in separate trays varying the pH and the
precipitant concentration. In 0.01 M tri-sodium
citrate and 16% PEG6000 rectangular single
crystals grew within a day. Crystals were flash
cooled after soaking in a cryoprotectant solution of
0.01 M tri-sodium citrate, 16% PEG6000, 20%
glycerol and 10% ethanediol. Crystals of the
USP11_DU-FYLIR complex diffracted to 1.3 Å
resolution and a dataset was collected at beamline
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I02 at Diamond Light Source, UK at a wavelength
of 0.97949 Å and a temperature of 100 K. Data
were processed using XDS (54) and AIMLESS (55)
and the structure was solved by molecular
replacement using individual DUSP and UBL
domain coordinates from the human USP11_DU
structure at 3.0 Å (PDB code 4MEL (20)) as search
model with PHASER (56). Data collection statistics
are summarized in Table 1.
Model building, refinement and validation
Model building and adjustments of the two
molecules of the asymmetric unit, each binding to a
peptide at the same location, were conducted using
COOT (57). Structure refinement was carried out in
PHENIX (58); data refinement statistics are shown
in Table 1. The quality of the model was assessed
by MOLPROBITY (59). The final model consists
of two USP11_DU molecules in the asymmetric
unit that associate via an interface area of 812 Å2,
but no tight packing at the interface occurs. Either
12 or all 14 residues of the FYLIR peptide were
observed in each copy of the asymmetric unit.
LigPlot+ (60) was used to analyze the interactions
of peptide residues with USP11_DU. In the final
model there are no Ramachandran outliers with
98.7% of residues located in favored regions.
Refinement statistics are summarized in Table 1.
All structure figures were generated with Pymol
(www.pymol.org).
Cell Lines
Cell lines (human glioblastoma KNS-42 and
U87, cervical carcinoma HeLa, mammary
carcinoma MCF7, pancreatic carcinoma Panc1, and
fibroblast NIH3t3 and BJ6 cell lines) except KNS-
42 were cultured at 37 °C in 5% CO2 in Dulbecco’s
modified Eagle´s media (DMEM; Sigma),
supplemented with 10% (v/v) Fetal Calf Serum
(FCS, Sigma), 4.5 g/L D-Glucose, 2 mM L-
glutamine and 100 units/ml penicillin and 100
units/ml streptomycin (Invitrogen). KNS-42 cells
were cultured in DMEM/F-12 (1:1). Cell passage
was carried out using 0.05% (w/v) trypsin-EDTA
(Invitrogen). U20S-DR3-GFP reporter cell lines for
homologous recombination were a kind gift from
Jeremy Stark (City of Hope, Duarte, CA).
DNA repair reporter assays
U20S reporter cell lines were simultaneously co-
transfected with siRNA using Dharmafect1
(Dharmacon) and DNA (RFP-USP11 or RFP-
USP11 L208F, S242R and ISce1 endonuclease
expression constructs) using FuGene6 (Promega).
The media was replaced after 16 hours and cells
were grown for a further 48 hours before harvesting
with trypsin and fixation in 2% paraformaldehyde
(Sigma) in PBS. Using a CyAn flow cytometer, a
minimum of 10,000 cells were analysed for each
sample and RFP and GFP double positive cells
were scored and normalised to RFP-transfection
efficiency. Each individual experiment contained
three technical repeats. Graphs shown are
combined data from six independent experiments
and error bars show SEM.
GET-FYLIR peptides
Synthetic peptides were obtained from
Biomatik or PeptideSynthetics. These harboured an
N-terminal red-fluorescent 5-
Carboxytetramethylrhodamine (TAMRA)
modified GET sequence composed of P21
(KRKKKGKGLGKKRDPCLRKYK) and 8R
(RRRRRRRR) fused to the FYLIR peptide
(AEGEFYKLKIRTPR), to create GET-FYLIR
(TAMRA-
KRKKKGKGLGKKRDPCLRKYKRRRRRRRR
AEGEFYKLKIRTPR-NH2). In the equivalent
scrambled GET control peptide the FYLIR
sequence was replaced by the scrambled sequence
APKFEIRRGTYKLE (GET-Scrambled).
Cell uptake
Cells treated with GET-FYLIR or GET-
Scrambled were analysed on an Astrios Cell sorter
using a 488 nm green laser (40,000 cells; gated on
live cells by forward/side scatter). Gmean was used
as the average cell intensity. All data sets were
combined for the statistical analysis. A Sidak’s
multiple comparisons test was applied. N refers to
the number of biological replicates.
Confocal microscopy
HeLa cells were plated onto 10 mm diameter
glass coverslips (1x105 cells/coverslip). Cells
treated with GET-FYLIR were fixed for 10 min in
3.7% (w/v) paraformaldehyde (Sigma), stained
with Hoechst 33342 1 µg/ml (Molecular Probes) for
a further 10 min, washed and mounted. Cells were
imaged using a LSM880C confocal microscope
(Zeiss, Germany). A 63x objective lens was used
with a 488 nm laser used for Hoechst 33342 and a
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561 nm DPSS laser for GET-FYLIR transduced
cells. Images were captured and processed using
ZEN software (Zeiss, Germany).
Cell viability
Cells were plated in 96-well plates (2.5x104
cells/well) and treated with GET-FYLIR (0-50 µM)
for 24 hours. Cells were also treated with GET-
Scrambled as a control. After treatment, cells were
washed with PBS and then incubated for 15 min at
37 °C with a 100 µl Presto Blue solution (10%
Presto Blue, Invitrogen in HBSS, Sigma). Change
in the fluorescence was measured using a plate
reader with the excitation/emission wavelengths set
at 560/590 nm (Infinite® 200 PRO, TECAN), with
untreated cells used as a control. All data sets were
combined for the statistical analysis. A Sidak’s
multiple comparisons test was applied. N refers to
the number of biological replicates.
Cell cycle analysis
Cells were plated in 24 well plates (1x105
cells/well) and treated with GET-FYLIR (20 µM)
for 24 hours. The cells were treated with trypsin,
detached from the plate and centrifuged at 200 g for
5 min. The supernatant was aspirated and the cells
were resuspended in PBS. The cells were fixed in
70% ethanol for 1 hour at 4 °C. The cells were
washed with PBS and incubated in propidium
iodide staining solution (0.1% (v/v) Triton X-100,
10 μg/ml PI (Sigma) and 100 μg/ml DNase-free 
RNase A in PBS) for 30 min at room temperature.
Cells were analyzed using an FC500 flow
cytometer (Beckman Coulter) equipped with a 488
nm laser, data from at least 10000 cells were
acquired for each sample. Cells were gated based
on forward and side scatter and doublets excluded
by height/area analysis. Cell cycle percentages
were calculated by curved fit using Weasel V3.0
(Walter and Eliza Hall Institute of Medical
Research). Data shown are representative. All data
sets were combined for the statistical analysis. A
Sidak’s multiple comparisons test was applied. N
refers to the number of biological replicates. All
curves and statistical analyses were produced using
Prism 7 (GraphPad Software).
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Table 1 Crystallographic data collection and refinement statistics
USP11_DU-FYLIR
(AEGEFYKLKIRTPR)
Data collection
Space group P21
Cell dimensions
a, b, c (Å) 65.77, 45.51, 100.61
() 102.68
Resolution (Å) 1.30
Rmerge 0.054 (0.678)*
Rpim 0.027 (0.409)
I / I 15.1 (2.1)
CC1/2 0.999 (0.799)
Completeness (%) 98.3 (89.6)
Redundancy 4.1 (3.4)
Wilson B-factor (Å2) 13.8
Refinement
Resolution range (Å) 49-1.35
No. of reflections 140596 (13740)
Rwork / Rfree 0.157/0.178
No. atoms
Protein 3986
Non-peptide ligand 38
Water 649
B-factors (Å2)
Protein 19.66
Peptide 28.07
Water 32.36
R.m.s. deviations
Bond lengths (Å) 0.015
Bond angles () 1.35
*Values in parentheses are for highest-resolution shell.
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Figure 1. Discovery of USP11 binding sequences. (A) Schematic representation of the human USP11
domain structure. The N-terminal DUSP-UBL domains used as bait in the next generation phage display
(NGPD) experiments (USP11_DU) are labelled and depicted in green and purple, respectively. (B) Flow
chart of the NGPD approach. Three iterative rounds of phage selection (panning) against USP11_DU were
carried out and the eluted phage were bound to the target (USP11_DU) and an unrelated control protein in
parallel. The phagemid vectors from the output phage isolated against the target and control proteins were
isolated and the DNA region encoding the peptides was amplified and deep sequenced. Peptide sequences
seen to be enriched against the target protein compared to the control were listed and motifs identified. (C)
Amino acid sequence motifs identified by the MEME algorithm after the third round of biopanning. (D)
ITC data of USP11_DU with FYLIR (AEGEFYKLKIRTPQ) and LxLL (AEGEFLELLKASRW) peptides.
Thermograms (top) and binding isotherms (bottom) fitted using a one binding site model with associated
KD values are shown. DP, differential power.
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Figure 2. Molecular basis of USP11-FYLIR peptide interaction (A) Cartoon representation of the
USP11_DU-FYLIR peptide complex crystal structure. The USP11 DUSP and UBL domains are depicted
in green and purple, respectively with the FYLIR peptide (AEGEFYKLKIRTPR) shown in yellow (B)
Electrostatic potential surface representation of USP11_DU in complex with the FYLIR peptide in yellow
cartoon representation. Side chains are shown as sticks in the same orientation as in A. (C) Close-up view
of the molecular basis of the interactions. The peptide is bound to the USP11 UBL domain, with residues
5-12 predominantly contributing to the interaction. Key residues involved in the interaction are labelled and
shown as sticks. Colour code is the same as in A. (D) Schematic representation of FYLIR peptide–USP11
interactions generated using Ligplot+ (60). Peptide residues are labelled in brown, whereas USP11 residues
are labelled in purple. Hydrogen bonding interactions are indicated as purple, dashed lines and USP11
residues engaging in hydrophobic interactions with the peptide are depicted in purple. Crescent shapes
indicate USP11 binding pockets involved in FYLIR peptide binding.
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Figure 3. Sequence alignment of USP11, USP4 and USP15 DU domains. Structure-based sequence
alignment using PROMALS3D (61) of human USP11 (PDB code 4MEL (20)), USP15 (PDB code: 3T9L
(21)) and USP4 (PDB code: 3JYU, SGC, unpublished) with secondary structure elements above the
sequences indicated (e=strand; h=helix). The DUSP domain is shaded green, whereas the UBL domain is
shaded in purple. Sequence conservation is depicted as per PROMALS3D default representation (bold and
uppercase letters (such as G); aliphatic residues (I, V, L): l; aromatic residues (Y, H, W, F): @; hydrophobic
residues (W, F, Y, M, L, I, V, A, C, T, H): h; alcohol residues (S, T): o; polar residues (D, E, H, K, N, Q,
R, S, T): p; tiny residues (A, G, C, S): t; small residues (A, G, C, S, V, N, D, T, P): s; bulky residues (E,
F, I, K, L, M, Q, R, W, Y): b; positively charged residues (K, R, H): +; negatively charged residues (D, E):
-; charged (D, E, K, R, H) with the exception that identical residues are indicated using an asterisk symbol.
USP11 UBL domain residues located at the interface upon peptide binding are highlighted in red.
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Figure 4. Molecular basis of FYLIR peptide USP11 specificity (A) Close-up views of FYLIR peptide
binding to the ‘major pocket’ in the USP11 UBL domain (left panel) compared to USP15 (centre panel)
and USP4 (right panel), where steric clashes occur when the peptide is modelled into the same position
(highlighted by a dashed ellipse). Key residues involved in the interaction (USP11) or preventing peptide
binding (USP15, USP4) are depicted in cyan and labelled. (B) Close-up views of electrostatic surface
representations of FYLIR peptide binding to the ‘major pocket’ in the USP11 UBL domain (left panel)
compared to USP15 (centre panel) and USP4 (right panel), where the binding pocket is occluded. (C) ITC
data of FYLIR peptide with USP11_DU, USP4_DU and USP15_DU, showing that peptide-ligand binding
is highly specific for USP11.
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Figure 5. Effects of a UBL binding site mutant on peptide recognition and homologous recombination
(A) ITC data of the USP11_DU L208F, S242R double mutant that mimics USP15 showing that binding of the
FYLIR peptide ligand is completely abolished upon mutating residues in the UBL pocket (referred to as
major pocket). (B) ITC data of titrations of peptide AEGEFLRLLNFTKP harbouring motif 2 (LxLL) with
USP11_DU L208F, S242R. The interaction of this peptide ligand with USP11 is also abolished upon mutating
residues in the UBL pocket. (C) Homologous Recombination GFP-reporter assays with USP11 siRNA and
RFP-USP11 WT or mutant USP11 L208F, S242R. Each individual experiment contains three technical repeats.
Data presented is the overall mean calculated from the means of each individual experiment (n=6). % GFP
and RFP double positive cells were normalised to RFP transfection efficiency; error bars = SEM; p-values
were computed using the Welch’s T-test and are shown as *** p<0.0005, ** p<0.005 and * p<0.05 (NTC
v siUSP11: p=0.0003; siUSP11 v siUSP11+WT: p=0.0017; siUSP11 v siUSP11+USP11L208F, S242R:
p=0.0049).
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Figure 6. Cellular effects of FYLIR peptide agent. (A) GET-FYLIR has cytoplasmic, nuclear and
nucleolar localization. HeLa cells were treated with GET-FYLIR (10 µM) for 24 h and assessed by confocal
microscopy (nuclei were counterstained with Hoechst 33342). The white scale bar is 20 µm. (B) GET-
FYLIR decreases cell viability cell-type specifically and dose dependently. Cell viability (Presto Blue
assay) was assessed after 24 h incubation with GET-FYLIR (0, 10, 20 and 50 µM) in KNS-42, U87, BJ6,
HeLa, NIH3t3, MCF7 and Panc1 cells. Cell viability was expressed as percentage of cell viability ± s.d.
(n=3 biological repeats) (C) GET-FYLIR induces S phase arrest cell-type specifically. Cell cycle analysis
was conducted using NIH3t3 cells (n=5 biological repeats) and Panc1 (n=7 biological repeats) cells
untreated or incubated with GET-FYLIR (20 µM) for 24 h. Cells were fixed, stained with propidium iodide
staining solution and analysed for DNA content. The distribution and percentage of cells in SubG0, G0, S,
G2 and super G2 phase of the cell cycle are indicated.
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